A therapeutic HIV vaccine was found to have no effect on suppressing HIV in the absence of antiretroviral therapy (ART), reveals a new study.
A randomized, double-blind, placebo-controlled clinical trial found no benefit, but could offer researchers much needed insights for future cure efforts. The authors say their results represent yet another addition to the burgeoning body of evidence to suppress HIV.
Feuding Antibodies Blocked High-profile HIV Vaccine Trial
A high-profile HIV vaccine trial that was shown to work in just under a third of patients may have been hindered by feuding antibodies, says US researchers.
Advertisement
‘Therapeutic vaccination boosts individual's immune responses against HIV, which enables them to control the virus without Antiretroviral therapy (ART).’
Tweet it Now
Although ART has provided tremendous benefits for prolonging lifespans of those infected with HIV, the regimens have not been able to eliminate the virus from its reservoirs within the body.
Therapeutic vaccination has emerged as a potential strategy to boost people's own immune responses against HIV so they can control the virus without ART.
![Complex Protein may Help HIV Vaccine Development]( "Complex Protein may Help HIV Vaccine Development")
Scientists at Duke University have taken aim at what may be an Achilles' heel of the HIV virus.
To study the effectiveness of such an approach, Michael Sneller, Anthony Fauci and colleagues recruited a cohort of HIV-infected individuals from the United States and Canada who had initiated ART shortly after their initial diagnosis.
During a 36-week period where all participants continued ART treatment, 14 people received four injections of a therapeutic HIV vaccine and 15 individuals were administered saline as a control.
When ART was discontinued for 16 weeks under the supervision of the researchers, there was no difference observed in viral rebound between placebo and vaccine groups.
Surprisingly, four people in the placebo group exhibited spontaneous HIV suppression - a substantially greater proportion than would be predicted by the estimated prevalence of so-called "elite HIV controllers" in the general population.
A related Focus by Nelson Michael discusses how these findings further demonstrate the value and importance of well-designed placebo-controlled trials.
Source: Eurekalert
Complex Protein may Help HIV Vaccine Development
Scientists at Duke University have taken aim at what may be an Achilles' heel of the HIV virus.
Advertisement
To study the effectiveness of such an approach, Michael Sneller, Anthony Fauci and colleagues recruited a cohort of HIV-infected individuals from the United States and Canada who had initiated ART shortly after their initial diagnosis.
During a 36-week period where all participants continued ART treatment, 14 people received four injections of a therapeutic HIV vaccine and 15 individuals were administered saline as a control.
When ART was discontinued for 16 weeks under the supervision of the researchers, there was no difference observed in viral rebound between placebo and vaccine groups.
Surprisingly, four people in the placebo group exhibited spontaneous HIV suppression - a substantially greater proportion than would be predicted by the estimated prevalence of so-called "elite HIV controllers" in the general population.
A related Focus by Nelson Michael discusses how these findings further demonstrate the value and importance of well-designed placebo-controlled trials.
Source: Eurekalert
In Infants, HIV Vaccines Elicit Immune Response
A new analysis of two HIV vaccine trials that involved pediatric patients shows that the investigational vaccines stimulated a critical immune response in infants born to HIV-infected mothers.
Advertisement
 New HIV Vaccine Candidate Molecule DevelopedA new sugar-protein molecule elicits a good immune response against the HIV virus in rabbits, and shows potential to be used in a vaccine against the infection | Advertisement
|
Advertisement
Recommended Readings
Latest AIDS/HIV News
The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.
In the United States, African American women make up only 26% of female PrEP users, yet they account for 57% of new infections among women.
Scientists have made a groundbreaking discovery in the fight against HIV/AIDS with the successful resolution of the enigmatic immune-evading HIV protein complex.
Tailored quit-smoking programs are designed to address the risks associated with comorbidity in individuals living with HIV.
DNA editing tool CRISPR-Cas13 helps diagnose and signal the presence of HIV antibodies in HIV patients.
